The 24-month outcomes from the trial demonstrate a durable and superior treatment effect of DCB versus PTA with significantly higher primary patency, lower CD-TLR, and similar functional status improvement with fewer repeat interventions. (Randomized Trial of IN.PACT Admiral Drug Eluting Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; and IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461).

Supplemental Digital Content is available in the text.

In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906).

While the number of physicians performing CAS continues to increase, MAE rates seen in this registry (4.4%) are well within an acceptable range, as was first seen in the SAPPHIRE randomized trial (4.8%). A significant decrease in MAE was seen in patients with anatomic risk compared with physiologic risk factors. The SAPPHIRE Worldwide Registry supports the use of CAS as an alternative to CEA in patients who are at high-risk for surgery due to anatomic risk factors.

P eripheral artery disease (PAD) is common, affecting between 8 and 12 million US residents. [1][2][3] Treatment strategies are well defined for aortoiliac vessels, 4 yet the initial success and durability of endovascular therapy in the femoropopliteal artery is limited by the diffuse nature of the disease, presence of calcification, heavy plaque burden, and high prevalence of total occlusion. Furthermore, dynamic forces (compression, torsion, bending, lengthening, Background

E ndovascular intervention has become the primary mode of revascularization for patients with symptomatic femoropopliteal peripheral artery disease. Multiple modalities of treatment exist; however, the mainstay is percutaneous transluminal angioplasty (PTA) and implantation of a bare metal stent (BMS). 1 Angioplasty, though effective in luminal gain, has been associated with restenosis rate of up to 60% at 12 months. 2,3 Although implantation of a BMS has been shown to reduce this restenosis rate by nearly half, 2-7 BMSs are associated with inherent problems, including in-stent restenosis, thrombosis, and stent fracture. 8-10 See Editorial by Sethi and Parikh To overcome the limitations of standard interventions such as PTA or BMSs, drug-coated balloons (DCBs) were developed in hopes of improved patency over the long term,

The interwoven nitinol design stent is a stent that achieves an excellent primary patency but further maintains the durability of the stent through 36 months. Optimal stent deployment remains critical to the performance of this stent device and requires optimal vessel preparation. © 2017 Wiley Periodicals, Inc.

Supplemental Digital Content is available in the text.